Timolol: Clinical Trials

47 trials of Timolol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 4 unknown, 3 terminated, 2 withdrawn. 47 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 347Completed 37, Unknown 4, Terminated 3, Withdrawn 2, Recruiting 1
Phase 21Unknown 1

Follow Timolol: new trials by email Literature Review of Timolol trials Research Report on Timolol

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Timolol 0.5% eye drops and betamethasone valerate 0.1% cream, Betamethasone valerate 0.1% cream - Paronychia, EGFR-TKI
Phase 3RecruitingQueen Mary Hospital, Hong Kong402024-10-092024-10-18
Efficacy and Safety of Timolol for TKI Induced Paronychia
Topical Timolol, Betamethasone Valerate - Paronychia
Phase 3UnknownQueen Mary Hospital, Hong Kong402023-04-012023-12-20
Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema
Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide, Injections of 1.25 mg of intravitreal bevacizumab with artificial tears - Diabetic Macular Edema
Phase 2 / Phase 3UnknownShahid Beheshti University of Medical Sciences622021-10-062021-10-19
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL - Open-angle Glaucoma, Ocular Hypertension
Phase 3CompletedSanten Pharmaceutical Co., Ltd.2192019-01-202023-07-14
Beta Adrenergic Antagonist for the Healing of Chronic DFU
Timolol, Non biologically active gel - Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers
Phase 3CompletedVA Office of Research and Development482018-07-242025-05-08
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic - Primary Open-angle Glaucoma
Phase 3TerminatedLaboratorios Sophia S.A de C.V.512017-11-062025-03-06
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
PRO-122, Krytantek Ofteno® - Primary Open Angle Glaucoma, Ocular Hypertension
Phase 3CompletedLaboratorios Sophia S.A de C.V.602016-04-012019-12-09
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 3CompletedInotek Pharmaceuticals Corporation3032015-09-012016-12-06
Stop Retinal Ganglion Cell Dysfunction Study
Latanoprost, Bimatoprost, Travoprost - Glaucoma
Phase 3TerminatedUniversity of Miami282015-09-012025-08-26
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5% - Glaucoma, Open-Angle, Ocular Hypertension
Phase 3CompletedAllergan5282014-12-152021-07-28
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle - Glaucoma, Open-Angle, Ocular Hypertension
Phase 3CompletedAllergan5942014-12-152020-06-11
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
T2347, Xalacom - Open Angle Glaucoma, Ocular Hypertension
Phase 3CompletedLaboratoires Thea2422014-12-012017-04-28
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution - Glaucoma, Ocular Hypertension
Phase 3WithdrawnAllergan2013-07-012013-07-18
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension
Phase 3CompletedBausch & Lomb Incorporated4202013-01-312018-11-07
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension
Phase 3CompletedBausch & Lomb Incorporated4202013-01-012018-11-21
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle - Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Phase 3CompletedAlcon Research1842012-09-012015-07-23
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol - Ocular Hypertension, Open-angle Glaucoma
Phase 3CompletedSanten Oy4012011-03-012012-06-08
Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel
Timolol + LCP, LCP - Melanoma
Phase 3TerminatedCentre Hospitalier Universitaire de Nice252011-02-162026-06-17
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Timolol/ FDC/ Placebo/ Tafluprost - Ocular Hypertension, Open-angle Glaucoma
Phase 3CompletedSanten Oy6002011-02-012013-03-13
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension
Phase 3CompletedAlcon Research3282010-11-012014-04-10

Showing 20 of 47. Sign in to see all of them.

Conditions studied

Ocular Hypertension (34)  ·  Glaucoma, Open-Angle (29)  ·  Glaucoma (23)  ·  Hypertension (4)  ·  Fibrosis (2)  ·  Hypertension, Portal (2)  ·  Paronychia (2)  ·  Esophageal and Gastric Varices (1)  ·  Gastrointestinal Hemorrhage (1)  ·  Glaucoma, Angle-Closure (1)  ·  Hydrophthalmos (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)  ·  Melanoma (1)  ·  Varicose Veins (1)

Sponsors

Alcon Research (12)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8)  ·  Allergan (5)  ·  Bausch & Lomb Incorporated (2)  ·  Laboratorios Sophia S.A de C.V. (2)  ·  Queen Mary Hospital, Hong Kong (2)  ·  Santen Oy (2)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  Inotek Pharmaceuticals Corporation (1)  ·  Laboratoires Thea (1)  ·  Merck Sharp & Dohme LLC (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Pfizer (1)  ·  Santen Pharmaceutical Co., Ltd. (1)  ·  Shahid Beheshti University of Medical Sciences (1)

Countries

United States (18)  ·  United Kingdom (5)  ·  France (4)  ·  Germany (4)  ·  Belgium (3)  ·  Colombia (3)  ·  Hong Kong (3)  ·  Italy (3)  ·  Singapore (3)  ·  Spain (3)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Finland (2)

Top investigators

Auli Ropo, M.D. (2)  ·  Jason Vittitow (2)  ·  Pamela Smith, B.S. (2)  ·  Andrew Burroughs, M.D. (1)  ·  Cadmus C Rich, MD,MBA,CPE (1)  ·  Clemens Vass, M.D. (1)  ·  Eva Ruzickova, M.D. (1)  ·  Guadalupe Garcia-Tsao, M.D. (1)  ·  Guna Laganovska, M.D. (1)  ·  Hannu Uusitalo, M.D., Prof. (1)  ·  Ingeborg Stalmans, Professor (1)

Results publications

PMID 19427617, PMID 29194198, PMID 35643967, PMID 36378864, PMID 16306522, PMID 17459480, PMID 18538406, PMID 19303163, PMID 19365194, PMID 20142538, PMID 20346127, PMID 21851642, PMID 25429421, PMID 25447269, PMID 25613811, PMID 26875002, PMID 27210275, PMID 27450828, PMID 2788589, PMID 29680880, PMID 32513257, PMID 34724172, PMID 38376643, PMID 41737851

NIH funding

2014 (2), R01DK046580 (1), R01EY014957 (1)